Update in juvenile myositis. by Nistala, K & Wedderburn, LR
CREVIEW CURRENTOPINION Update in juvenile myositisopyright © Lippincott Will
www.co-rheumatology.coma b,cKiran Nistala and Lucy R. WedderburnPurpose of review
This update on childhood idiopathic inflammatory myopathies (IIMs) reviews recent progress in the field of
translational science and clinical research over the past 12–18 months.
Recent findings
Several new studies, including results from the international genome-wide association study, point to
abnormalities of the adaptive immune system in childhood IIMs. Circulating T-follicular helper cells
promote plasma cell differentiation and have been found in high levels in juvenile dermatomyositis
(JDM), which may account the frequency of autoantibodies seen in this disease. One of the latest to be
identified in JDM targets the protein NXP-2 and is associated with an increased risk of calcinosis in
young patients. The first randomized controlled clinical trial in refractory adult and childhood IIMs was
reported this year. B-cell depletion with the anti-CD20 antibody, rituximab, failed to achieve its primary
end point, but patients with JDM did show good improvement in disease activity. A new international
definition of disease remission in JDM has been agreed, which will aid disease assessment in future
therapeutic trials.
Summary
The challenges of studying a rare disease such as JDM have been overcome by several collaborative
studies and have led to significant progress in understanding the cause, treatment and prognosis of
childhood IIMs.
Keywords
autoantibodies, B-cell depletion, juvenile dermatomyositisaCentre for Rheumatology, University College London, bRheumatology
Unit, UCL Institute for Child Health, London and cArthritis Research UKINTRODUCTION
The childhood idiopathic inflammatory myopa-
thies (IIMs) are a group of rare but serious multi-
system diseases of which the most common is
juvenile dermatomyositis (JDM), whereas juvenile
polymyositis is seen in less than 5% of cases in most
cohorts. It is increasingly clear that the childhood
IIMs are in fact relatively heterogeneous: recent
advances have shed new light on biomarkers and
predictors of this heterogeneity. In this review, we
will consider novel developments in our under-
standing of cause as well as new studies of the
clinical assessment, treatment and outcomes of
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Over the past year, there has been significant prog-
ress in understanding the cause of childhood IIMs,
including completion of an international genome-
wide association study of IIM, novel studies linking
JDM with environmental factors, and developments
in the field of immunology.iams & Wilkins. UnauthoGenetics
Investigators from MYOGEN, an international myo-
sitis genetics consortium, have carried out the first
genome-wide association study of adult and paedi-
atric cases of dermatomyositis from across the US
and Europe. As well as confirming the known associ-
ation with human leukocyte antigen (HLA) region,
the results have identified several genes not pre-
viously linked with IIM [1]. These results offer excit-
ing new avenues for future research, to explore therized reproduction of this article is prohibited.
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KEY POINTS
 A new international definition of remission in JDM has
been agreed based on creatine kinase, CMAS, PGA
and MMT8 scores.
 A randomized controlled study of B-cell depletion in IIM
failed to achieve its primary end point, but did show
improvements in disease activity, most noticeably in the
JDM subgroup.
 New autoantibody associations identified in JDM may
help clinician stratify patients for future
treatment studies.
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phisms and how these may alter the risk of muscle
inflammation. In a separate genetics study, Chinoy
et al. [2] studied the genetic association of the
nuclear factor kappa B (NF-KB), a known signalling
intermediary in inflammation, with IIMs of both
adults and children. An allele of the inhibitor of kappa
B-like (IKBL) gene, which is part of the NF-KB family,
was associated with myositis cases when compared
to controls, but after controlling for linkage disequi-
librium with the HLA 8.1 haplotype, this effect
was lost.
The above data reinforce the hypothesis that
JDM is a complex genetic disorder with each genetic
association having a modest effect on the risk of
acquiring JDM. However, the study of monogenic
human disorders also offers insights into the cause
of JDM; patients with the rare inflammatory
disorder, CANDLE syndrome – chronic atypical
neutrophilicdermatosis with lipodystrophy and
elevated temperature – share clinical and immuno-
logical features with JDM, including myositis, lip-
odystrophy and a prominent interferon (IFN)-a
signature in whole blood samples. Mutations in
the immunoproteasome, a family of proteins that
process degraded intracellular proteins, have been
identified as the cause of CANDLE syndrome [3
&
].
This is of particular interest to IIMs, as several related
pathways involved in the trafficking and folding
of proteins within the endoplasmic reticulum have
already been implicated in pathogenesis of IIMs
[4].
Environment
It has been a longstanding clinical observation that
sunlight can precipitate disease flares in JDM and
juvenile systemic lupus erythematous (SLE). A
recent study [5] suggests that exposure to ultraviolet
(UV) light could also trigger disease onset; the
authors found that the intensity of UV light in
the month prior to disease presentation increasedCopyright © Lippincott Williams & Wilkins. Unau
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myositis. This risk was only detectable in patients
positive for the p155/140 myositis-associated
autoantibodies who represented 30% of this cohort,
which is in line with previous studies [6]. This raises
the interesting question of how sunlight might
promote the breakdown of B-cell tolerance. The
target for the p155/140 antibody has been identified
as the transcription factor, transcriptional inter-
mediary factor (TIF)-1, a member of the tripartite
motif (TRIM) family of proteins [7]. The authors
speculate that sunlight may up-regulate interferon
type 1 cytokines which secondarily up-regulate
the TRIM proteins leading to an autoantibody
response.
Although JDM patients are advised to use sun
block and avoid sun exposure, this could lead to
reduced levels of vitamin D. Vitamin D metabolites
are important in inducing tolerogenic dendritic
cells [8], so one inadvertent consequence of sun
avoidance could be a failure of immunoregulation
which will result in increased disease activity.
To test this hypothesis, Robinson et al. [9] measured
25-hydroxylated vitamin D in 21 JDM patients and
found that serum levels inversely correlated with
physician’s global disease activity scores, after con-
trolling for vitamin D supplementation and race,
which are two known influences on vitamin D
status. Sadly, vitamin D as a therapy has yet to show
significant benefits as a treatment for autoimmune
disease [10].
Immunity
Researchers have investigated the immunonopa-
thology of childhood IIMs by detecting abnormal-
ities in the peripheral blood compartment and
muscle tissue taken during diagnostic procedures.
Peripheral blood compartment: It is increasingly
clear that the autoantibody status of patients with
JDM is strongly associated with distinct clinical
phenotypes [6]. However, thus far, it is unclear if
autoantibodies represent an epiphenomenon of
failed tolerance or themselves contribute to the
pathogenic process. To investigate this, Balboni
et al. [11] screened sera from 36 JDM patients to
detect autoantibodies and correlated results with
serum interferon alpha activity detected by a func-
tional reporter cell assay. They found that serum
with antibodies against Ro, La, Smith and ribonu-
clearprotein (RNP) had an increased capacity to
induce (IFN-a), although they did not test if this
was a direct or indirect effect of the circulating
autoantibodies.
In a seminal paper, the paediatric rheumatology
team at Baylor (Texas, USA) explored the immuno-
logical mechanisms that may account for highthorized reproduction of this article is prohibited.
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They identified a subset of circulating T cells, express-
ing the chemokine receptor CXCR5, which are likely
the human equivalent of murine T-follicular
helper cells (Tfh) [12]. These human CXCR5þ Tfh
support the differentiation of naı¨ve B cells into
antibody-producing plasmablasts in an IL-10, indu-
cibleT cell co-stimulator (ICOS)and IL-21-dependent
manner, and were present at a higher frequency in
the blood of patients with JDM when compared
with age-matched controls. Moreover, circulating
CXCR5þ Tfh correlated with the frequency of
plasmablasts in JDM, but only in patients with active
disease. The authors did not assess autoantibody
status, but it would be interesting to test if Tfh/
plasmablasts were particularly enriched in patients
with particular myositis-associated autoantibodies.
Other groups have tested the importance of the
JDM peripheral blood mononuclear cell compart-
ment in disease pathology, by examining changes in
cell frequencies over time and correlating this with
alterations in disease activity. Ernste et al. [13] found
a positive correlation between changes in myeloid
dendritic cell compartment and extramuscular dis-
ease activity and a negative correlation between the
plasmacytoid dendritic cell frequency and muscle
disease activity. However, in both cases, correlations
were relatively weak, which may reflect the hetero-
geneity of the patient population or the limitations
of using the peripheral blood compartment as a
surrogate for inflammatory reactions of the skin
or muscle.
Muscle: Two new studies examine the mechan-
isms that control gene expression in myositic tissue.
In the first, the authors investigate the regulation of
vascular cell adhesion molecule (VCAM)-1, an
inflammatory mediator that is enriched in JDM
muscle tissue. Previous studies have identified a role
for micro-RNA (miR)-126, one of a family of small
non-coding RNAs that bind and degrade messenger
RNA, in regulating VCAM-1 expression [14]. In
muscle biopsies from untreated JDM patients,
miR-126 was significantly decreased compared with
controls, and these patients had higher muscle
VCAM-1 expression [15]. In their second study
[16
&
], the group investigated the epigenetic regula-
tion of muscle gene expression by carrying out
whole-genome DNA methylation profiling on
muscle tissue from JDM patients prior to treatment.
The authors identified 27 genes that were differ-
entially methylated between JDM and control
muscle. None of these was linked with the endo-
plasmic reticulum (ER) stress or type I interferon,
pathways known to be involved in JDM. However,
six genes within the homeobox family were differ-
entially methylated, including the gene WT1opyright © Lippincott Williams & Wilkins. Unautho
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ation with Wilms tumour), which was significantly
hypomethylated in JDM. Consistently with this,
WT1 protein levels were significantly increased in
JDM muscle, which may play a role in maintaining
the pool of pluripotent muscle stem cells in
regenerating muscle.
Diagnosis and clinical assessment
One of the ongoing challenges in the management
of JDM has been the difficulty in identifying residual
disease activity after treatment. Lazarevic et al. [17
&
]
used a Paediatric Rheumatology International Trials
Organization (PRINTO) cohort of JDM patients off
treatment to define criteria for inactive disease.
Focusing on available clinical assessment tools, they
found that three of the following four criteria best
identified inactive disease: creatine kinase 150 U/l or
less, childhood myositis assessment score (CMAS) at
least 48, physician global assessment (PGA) 0.2 or
less and manual muscle testing (MMT)-8 score of
78 or less [17
&
]. It is of note that three of these four
criteria focus on muscle disease activity, which may
underestimate inflammation in other organs, such
as skin and gut.
Several groups have investigated whether the
addition of MRI can improve the assessment of
patients with JDM. Ladd et al. [18] examined the
prognostic value of pre-treatment MRI scans of the
pelvic and thigh muscle. The overall severity of MRI
changes did not correlate with outcome, nor did the
extent of muscle involvement, but signal abnormal-
ity in the subcutaneous fat was a specific (but not
sensitive) indicator of an aggressive disease course
[18]. In a separate study [19], whole body MRI
(WB-MRI) was used to assess inflammation of
muscle, fascia and subcutaneous fat in 41 JDM
patients at presentation and repeated in 18 patients
at a median follow-up of 9 months. As expected,
WB-MRI scores strongly correlated with MMT-8 and
CMAS, but more interestingly, at follow-up, MRI
identified more patients in remission (defined by
PRINTO criteria [17
&
]) than MMT. This may reflect
alternative explanations for muscle weakness such
as steroid atrophy or disuse, than are mistakenly
attributed to disease activity. Further larger-scale
studies are needed to confirm the utility and cost-
effectiveness of MRI in clinical practice and agree a
common standard for scoring of MRIs, which cur-
rently varies between centres [20].
Therapy
The year 2013 witnessed the publication of the first
double-blind randomized controlled trial (RCT) of a
therapeutic agent in IIMs, and reflects a major
achievement of collaboration across the disciplinesrized reproduction of this article is prohibited.
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and neurology. This trial examining the efficacy
of the anti-CD20 antibody, rituximab, was con-
ducted in both adult (76 each of polymyositis and
dermatomyositis) and childhood IIMs (48 JDM), and
carried out across 31 sites in the US and Canada
[21
&&
]. To limit the duration of the placebo phase of
the trial, investigators undertook a staggered cross-
over design, with an 8-week delay between ‘early’
and ‘late’ rituximab-treated groups. On the basis of
anecdotal clinical data, results from trials of SLE, and
the prompt clearance of circulating B cells after drug
treatment with rituximab, it was assumed that the
drug would have a rapid onset of action. Unfortu-
nately, the trial did not meet its primary end point
to detect a difference in the time to reach definition
of improvement (DOI) in the early vs. late arms. This
result may have reflected a slower and less potent
effect of rituximab than expected. However, there
was encouraging news for paediatric rheumatolo-
gists, as patients with JDM showed a much greater
treatment effect between early and late groups when
compared with adult IIMs, but there were insuffi-
cient numbers to detect a significant difference.
Infections were the commonest serious adverse
events, including pneumonia in six, cellulitis in
six, urosepsis in two and herpes zoster in two. In
conclusion, more studies are needed before rituxi-
mab can be recommended as a rescue therapy
for JDM.
A retrospective case series showed encouraging
results for the use of mycophenolate mofetil (MMF)
in 12 patients with JDM [22]. In a retrospective
controlled study [23] of JDM, intravenous immuno-
globulin (IVIG) was found to reduce disease activity,
particularly in steroid-resistant patients.
Physical therapy is a routine part of the rehabil-
itation of IIMs in most specialist units, yet lacks a
strong evidence base. A new RCT to test the efficacy
of a 12-week home-based exercise programme and
see if this improves aerobic exercise capacity, iso-
metric muscle strength and perception of fatigue is
ongoing [24].
With limited evidence to inform treatment
decisions in JDM, the dosing and duration of corti-
costeroid treatment and use of rescue therapies
for steroid-resistant patients vary widely between
centres. Over recent years, the North American
Childhood Arthritis and Rheumatology Research
Alliance (CARRA) have carried out consensus con-
ferences to develop standardized treatment guide-
lines for JDM. In their latest publication, CARRA
defines the clinical characteristics of patients with
JDM of moderate severity, and for these patients,
suggests a corticosteroid treatment regime begin-
ning at 2 mg/kg, weaning to 1 mg/kg by 14 weeks,Copyright © Lippincott Williams & Wilkins. Unau
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&&
]. Although the rate of
steroid weaning may be slow for those patients who
respond rapidly to treatment, overall these guide-
lines offer a useful synthesis of expert opinion
across the major international centres that treat
JDM.Prognosis and long-term outcomes
Long-term functional data in adult patients who
had JDM as children are still scarce; therefore, two
recent studies in such adults are important and both
suggest that functional outcomes for these patients
are far from optimal. A study [26
&
] of 39 adults who
had JDM, assessed at a median of 22 years post-
disease onset, showed that these patients had
reduced quality of life compared with age-matched
controls. A second study [27] assessed aerobic fit-
ness, in 36 JDM patients at 2–36 years after onset,
and found that 67% had reduced fitness as measured
by maximal oxygen uptake (VO2max) as a measure of
muscle function.
Although validated biomarkers with which to
predict outcomes are still lacking, progress has been
made in markers of clinical phenotypes, including
the clear demonstration that myositis-specific auto-
antibodies correlate with specific clinical features.
Analysis in a large US cohort has confirmed that the
juvenile IIMs are heterogeneous and can be clini-
cally divided by autoantibody status [28
&
]. The
presence of anti-nuclear matrix protein (NXP)-2
antibodies has recently been shown to be associated
with calcinosis in children with JDM [29
&
].
Two recent studies have investigated how age at
onset may affect disease type, features and prognosis
of JDM. In the first, children whose disease man-
ifested before the fifth birthday were seen to have
more ulcerative skin disease and oedema, and a
lower incidence of sclerodermatous overlap features
[30]: children with a younger age at onset were
treated more aggressively but achieved comparable
rates of remission by 2 years after diagnosis. The
second study [31] found that children whose JDM
starts before the age of 3 years had a milder disease
course but more atypical features.CONCLUSION
In conclusion, in recent years, work in the juvenile
myopathies specifically, as well as studies that have
combined both adults and children, have led to
many novel insights and developments in our
understanding. Clinical trials in this rare disease
are challenging, but the increasingly well organized
collaborative networks should facilitate these much-
needed studies in the future.thorized reproduction of this article is prohibited.
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